Risk Factors for All-Cause Mortality in Patients Diagnosed with Advanced Heart Failure: A Scoping Review

被引:0
|
作者
Kaur, Palvinder [1 ]
George, Pradeep Paul [1 ]
Xian, Sheryl Ng Hui [1 ]
Yip, Wan Fen [1 ]
Seng, Eric Chua Siang [1 ]
Tay, Ri Yin [2 ]
Tan, Joyce [2 ]
Chu, Jermain [3 ]
Low, Zhi Jun [3 ]
Tey, Lee Hung [3 ]
Hoon, Violet [4 ]
Tan, Chong Keat [4 ]
Tan, Laurence [5 ]
Aw, Chia Hui [6 ]
Tan, Woan Shin [1 ]
Hum, Allyn [2 ,3 ]
机构
[1] Hlth Serv & Outcomes Res, Natl Healthcare Grp, 3 Fusionopolis Link, Singapore 138543, Singapore
[2] Palliat Care Ctr Excellence Res & Educ, Singapore, Singapore
[3] Tan Tock Seng Hosp, Dept Palliat Med, 11 Jalan Tan Tock Seng, Singapore, Singapore
[4] Tan Tock Seng Hosp, Dept Cardiol, 11 Jalan Tan Tock Seng, Singapore, Singapore
[5] Khoo Teck Puat Hosp, Geriatr Med, Singapore, Singapore
[6] Palliat & Support Care, Woodlands Hlth Campus,2 Yishun Cent 2 Tower E, Singapore, Singapore
基金
英国医学研究理事会;
关键词
all-cause mortality; end-of-life; end-stage heart failure; palliative care; prognostication; unmet needs; REDUCED EJECTION FRACTION; SYSTOLIC BLOOD-PRESSURE; SHORT-TERM MORTALITY; PROGNOSTIC VALUE; POSTDISCHARGE OUTCOMES; AMBULATORY PATIENTS; RENAL-FUNCTION; PREDICTIVE-VALUE; PALLIATIVE CARE; NATRIURETIC PEPTIDE;
D O I
10.1089/jpm.2024.0067
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
Introduction: Identifying the evolving needs of patients with advanced heart failure (AdHF) and triaging those at high risk of death can facilitate timely referrals to palliative care and advance patient-centered individualized care. There are limited models specific for patients with end-stage HF. We aim to identify risk factors associated with up to three-year all-cause mortality (ACM) and describe prognostic models developed or validated in AdHF populations.Methods: Frameworks proposed by Arksey, O'Malley, and Levac were adopted for this scoping review. We searched the Medline, EMBASE, PubMed, CINAHL, Cochrane library, Web of Science and gray literature databases for articles published between January 2010 and September 2020. Primary studies that included adults aged >= 18 years, diagnosed with AdHF defined as New York Heart Association class III/IV, American Heart Association/American College of Cardiology Stage D, end-stage HF, and assessed for risk factors associated with up to three-year ACM using multivariate analysis were included. Studies were appraised using the Quality of Prognostic Studies tool. Data were analyzed using a narrative synthesis approach.Results: We reviewed 167 risk factors that were associated with up to three-year ACM and prognostic models specific to AdHF patients across 65 articles with low-to-moderate bias. Studies were mostly based in Western and/or European cohorts (n = 60), in the acute care setting (n = 56), and derived from clinical trials (n = 40). Risk factors were grouped into six domains. Variables related to cardiovascular and overall health were frequently assessed. Ten prognostic models developed/validated on AdHF patients displayed acceptable model performance [area under the curve (AUC) range: 0.71-0.81]. Among the ten models, the model for end-stage-liver disease (MELD-XI) and acute decompensated HF with N-terminal pro b-type natriuretic peptide (ADHF/proBNP) model attained the highest discriminatory performance against short-term ACM (AUC: 0.81).Conclusions: To enable timely referrals to palliative care interventions, further research is required to develop or validate prognostic models that consider the evolving landscape of AdHF management.
引用
收藏
页码:524 / 537
页数:14
相关论文
共 50 条
  • [41] Prediction of risk of diabetic retinopathy for all-cause mortality, stroke and heart failure Evidence from epidemiological observational studies
    Zhu, Xiao-Rong
    Zhang, Yong-Peng
    Bai, Lu
    Zhang, Xue-Lian
    Zhou, Jian-Bo
    Yang, Jin-Kui
    MEDICINE, 2017, 96 (03)
  • [42] Galectin-3 levels and long-term all-cause mortality and hospitalization in heart failure patients: a meta-analysis
    Cheng, Wenke
    Maciej, Rosolowski
    Thiele, Holger
    Buettner, Petra
    ESC HEART FAILURE, 2024, 11 (05): : 2481 - +
  • [43] Progression of Physical Frailty and the Risk of All-Cause Mortality: Is There a Point of No Return?
    Xue, Qian-Li
    Bandeen-Roche, Karen
    Tian, Jing
    Kasper, Judith D.
    Fried, Linda P.
    JOURNAL OF THE AMERICAN GERIATRICS SOCIETY, 2021, 69 (04) : 908 - 915
  • [44] Construction of a nomogram for predicting the risk of all-cause mortality in patients with diabetic retinopathy
    Zuo, Wenwei
    Yang, Xuelian
    FRONTIERS IN ENDOCRINOLOGY, 2025, 16
  • [45] Proton pump inhibitors and all-cause mortality risk among cancer patients
    Krishnan, Arunkumar
    Schneider, Carolin Victoria
    Walsh, Declan
    WORLD JOURNAL OF CLINICAL ONCOLOGY, 2025, 16 (01):
  • [46] Abdominal Obesity Is Associated With an Increased Risk of All-Cause Mortality in Patients With HFpEF
    Tsujimoto, Tetsuro
    Kajio, Hiroshi
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2017, 70 (22) : 2739 - 2749
  • [47] Left atrial expansion index predicts all-cause mortality and heart failure admissions in dyspnoea
    Hsiao, Shih-Hung
    Chiou, Kuan-Rau
    EUROPEAN JOURNAL OF HEART FAILURE, 2013, 15 (11) : 1245 - 1252
  • [48] DO CARDIOVASCULAR-DISEASE RISK-FACTORS PREDICT ALL-CAUSE MORTALITY
    NORRISH, A
    NORTH, D
    YEE, RL
    JACKSON, R
    INTERNATIONAL JOURNAL OF EPIDEMIOLOGY, 1995, 24 (05) : 908 - 914
  • [49] Sacubitril/valsartan improves all-cause mortality in heart failure patients with reduced ejection fraction and chronic kidney disease
    Wei-Chieh Lee
    Ting-Wei Liao
    Tien-Yu Chen
    Hsiu-Yu Fang
    Yen-Nan Fang
    Huang-Chung Chen
    Yu-Sheng Lin
    Shang-Hung Chang
    Mien-Cheng Chen
    Cardiovascular Drugs and Therapy, 2024, 38 : 505 - 515
  • [50] Sacubitril/valsartan improves all-cause mortality in heart failure patients with reduced ejection fraction and chronic kidney disease
    Lee, Wei-Chieh
    Liao, Ting-Wei
    Chen, Tien-Yu
    Fang, Hsiu-Yu
    Fang, Yen-Nan
    Chen, Huang-Chung
    Lin, Yu-Sheng
    Chang, Shang-Hung
    Chen, Mien-Cheng
    CARDIOVASCULAR DRUGS AND THERAPY, 2024, 38 (03) : 505 - 515